Jun. 11 at 2:40 PM
$AMRX The most interesting detail from the Goldman conference was not a new price target but management's emphasis on a multi-decade growth strategy built around biosimilars, specialty pharmaceuticals, and complex medicines. That is the narrative institutional investors are likely focusing on now rather than the legacy generic-drug business.
For investors with a 2–3 year horizon, the bigger question may not be whether AMRX reaches the current analyst target of
$17, but whether CREXONT adoption and the Kashiv acquisition justify earnings growth that could support a valuation materially above today's consensus targets. The analyst target range of
$16–
$19 appears to reflect near-term earnings expectations, while the longer-term biosimilar opportunity is not yet fully reflected in most published targets.
